fbpx

Stay Informed. Stay Competitive. Get Free Email Updates Dow 30 & Emerging Growth

Stay Informed. Stay Competitive.

Get Free Updates

Dow 30 & Emerging Growth

FATE

Fate Therapeutics, Inc.

  ( )

Page Views : 67598

vista's key points

  • Fate Therapeutic's cell therapy product candidate pipeline is comprised of immuno-oncology programs, including off-the-shelf NK- and T-cell product candidates derived from master iPSC lines, and an immuno-regulatory program developed to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation.

vista's key points

  • Fate Therapeutic's cell therapy product candidate pipeline is comprised of immuno-oncology programs, including off-the-shelf NK- and T-cell product candidates derived from master iPSC lines, and an immuno-regulatory program developed to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation.

company profile

 

vista's view

On January 4th, Fate announced the closing of an underwritten public offering of 5,122,807 shares of its common stock, which included 701,754 shares that were issued pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $85.50 per share. In addition,...

Read More

vp watchlist

The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.

Interviews

    Coming Soon

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.

Get Free Email Updates